<DOC>
	<DOCNO>NCT00799435</DOCNO>
	<brief_summary>People type 2 diabetes experience heart failure often people without diabetes . This may due increase stiffness heart result diabetes . This study examine whether exenatide , medication use treat diabetes , may beneficial effect heart people type 2 diabetes heart failure .</brief_summary>
	<brief_title>Evaluating Use Exenatide People With Type 2 Diabetes Diastolic Heart Failure</brief_title>
	<detailed_description>Diastolic heart failure life-threatening condition occur ventricle heart become stiff fully relax , prevent heart properly fill blood . The circulation blood back , blood collect body 's organ , primarily lung . However , people diastolic heart failure may normal ejection fraction , measure amount blood heart pump heart beat . Having type 2 diabetes may increase risk diastolic heart failure . Also , people heart failure type 2 diabetes likely experience poor health even death people heart failure . It possible diabetes lead increase stiffness ventricle aorta , main blood vessel heart empty . Exenatide , part class medication know glucagon-like peptide-1 ( GLP-1 ) receptor agonist , new medication currently use treat elevate blood sugar level people diabetes . Some study show class medication may positive effect heart blood vessel . The purpose study determine effect exenatide aortic leave ventricular stiffness people type 2 diabetes diastolic heart failure . This 12-week study enroll adult type 2 diabetes diastolic heart failure normal ejection fraction . At baseline study visit , participant undergo physical examination , blood pressure heart rate measurement , blood collection , echocardiogram obtain image heart , non-invasive test measure blood flow aorta . Participants randomly assign receive either exenatide usual care . Participants receive exenatide inject medicine twice day 12 week . At Week 4 , participant attend study visit adjust medication dosage report problem , Week 6 , study staff follow participant phone . All participant attend study visit Week 12 repeat baseline testing .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Stable New York Heart Association ( NYHA ) Class IIIV heart failure symptoms least 4 week study entry Diagnosis diastolic heart failure normal ejection fraction Admitted hospital diagnosis heart failure 12 month study entry Type 2 diabetes Unstable angina , heart attack , coronary artery bypass surgery , angioplasty 3 month study entry Angina exertion Technically inadequate echocardiogram Atrial fibrillation atrial flutter Severe valvular heart disease Significant kidney insufficiency ( serum creatinine great 2.0 mg/dL require hemodialysis ) Conditions may associate change marker fibrosis collagen turnover ( e.g. , ongoing active rheumatological disease , require significant antiinflammatory agent , immunosuppression , pulmonary fibrosis , active cancer ) Significant history active substance abuse Type 1 diabetes Type 2 diabetes require chronic insulin use study entry Active thiazolidinedione ( TZD ) use , TZDs show worsen volume retention may exacerbate sign and/or symptom heart failure Pregnant breastfeeding Hypertrophic cardiomyopathy</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Diastolic Heart Failure</keyword>
	<keyword>Aortic Stiffness</keyword>
	<keyword>Exenatide</keyword>
</DOC>